Europe radiotherapy market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-22
- Report ID: 144376
- Pages: 200
-
Format:
Short Description
Europe Radiotherapy Market, By Type (External-Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiotherapy/ Radiopharmaceuticals, Others), Product (External Beam Radiotherapy, Internal Radiotherapy Products, Radiotherapy Software, Systemic Radiotherapy Others), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Liver Cancer, Thyroid Cancer, Brain Cancer, Cervical Cancer, Spine Cancer, Others), End User (Hospitals, Radiation Therapy Centers, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2029
Market Definition
Radiotherapy is a type of treatment procedure that is mainly used to treat cancer disease by the usage of X-rays and similar forms of radiation technology. The method and procedure of radiotherapy have been advanced in terms of launching new treatment planning software and advanced features-based therapy modalities.
In radiotherapy treatment, high-energy based radiation rays are often used to damage cancer cells and stop them from growing and dividing. External radiation therapy has numerous types of advanced technology which is used in the treatment of cancer. External radiation therapy comprised of three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), proton beam therapy, image-guided radiation therapy (IGRT), stereotactic radiation therapy, and volumetric modulated ARC therapy (VMAT), among others.
Market Segmentation
Europe radiotherapy market is categorized into five notable segments which are based on type, product, application, end user, and distribution channel.
On the basis of type, the Europe radiotherapy market is segmented into external-beam radiation therapy, internal radiation therapy, systemic radiotherapy/radiopharmaceuticals, and others
On the basis of product, the Europe radiotherapy market is segmented into external beam radiotherapy, internal radiotherapy products, radiotherapy software, systemic radiotherapy, and others
On the basis of application, the Europe radiotherapy market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer, and others
On the basis of end user, the Europe radiotherapy market is segmented into hospitals, radiation therapy centers, specialty clinics, and others
On the basis of distribution channel, the Europe radiotherapy market is segmented into direct tender, retail sales, and others
Market Players
Some of the key market players for Europe radiotherapy market are listed below:
CANON MEDICAL SYSTEMS CORPORATION
Mirada Medical Limited
Mevion Medical Systems
VIEWRAY TECHNOLOGIES, INC. (VIEWRAY)
Elekta AB (pub)
Accuray Incorporated
IBA Worldwide
Eckert & Zeigler BEBIG
Xoft, a subsidiary of iCAD, Inc.
RaySearch Laboratories
Brainlab
Advanced Oncotherapy
Hitachi, LTD.
Sumitomo Heavy Industries, Ltd.
Siemens Healthcare GmbH
Koninklijke Philips N.V.
Ariane Medical Systems Ltd
ZEISS International
General Electric Company
SIT-S.I.T. Sordina IORT Technologies S.p.A.
CIVCO Radiotherapy
TABLE OF CONTENTS
1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF EUROPE RADIOTHERAPY MARKET 25
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 TYPE LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 VENDOR SHARE ANALYSIS 40
2.11 MARKET APPLICATION COVERAGE GRID 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTER'S 5 FORCES 49
5 REGULATIONS 50
5.1 BRACHYTHERAPY DEVICES REGULATIONS: 50
5.2 USE OF SOURCES FOR MANUAL BRACHYTHERAPY. 50
5.3 BRACHYTHERAPY SOURCES ACCOUNTABILITY. 50
5.4 EUROPE MEDICAL AGENCY REGULATION 51
5.5 UK 51
5.6 INDIA: 52
6 MARKET OVERVIEW 53
6.1 DRIVERS 55
6.1.1 GROWING PREVALENCE OF CANCER DISEASE 55
6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 59
6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 60
6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 60
6.2 RESTRAINTS 61
6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 61
6.2.2 COMPLEX NATURE OF RADIOTHERAPY 61
6.2.3 HIGH COST OF RADIOTHERAPY PROCEDURE 62
6.3 OPPORTUNITIES 62
6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 62
6.3.2 GROWING GOVERNMENT INITIATIVES TOWARDS CANCER TREATMENT 65
6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 65
6.4 CHALLENGES 66
6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 66
6.4.2 RISK OF RADIATION EXPOSURE 67
7 IMPACT OF COVID-19 ON EUROPE RADIOTHERAPY MARKET 68
7.1 IMPACT ANALYSIS ON DEMAND 68
7.2 CONCLUSION 68
8 EUROPE RADIOTHERAPY MARKET, BY TYPE 69
8.1 OVERVIEW 70
8.2 EXTERNAL-BEAM RADIATION THERAPY 73
8.2.1 IMAGE-GUIDED RADIATION THERAPY (IGRT) 74
8.2.2 PROTON BEAM THERAPY 74
8.2.3 STEREOTACTIC RADIATION THERAPY 74
8.2.4 INTENSITY MODULATED RADIATION THERAPY (IMRT) 74
8.2.5 THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT) 74
8.2.6 VOLUMETRIC MODULATED ARC THERAPY (VMAT) 74
8.2.7 OTHERS 75
8.3 INTERNAL RADIATION THERAPY 75
8.3.1 BRACHYTHERAPY 76
8.3.1.1 HIGH DOSE BRACHYTHERAPY 76
8.3.1.2 LOW DOSE BRACHYTHERAPY 76
8.3.2 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 76
8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 77
8.5 OTHERS 77
9 EUROPE RADIOTHERAPY MARKET, BY PRODUCT 79
9.1 OVERVIEW 80
9.2 EXTERNAL BEAM RADIATION THERAPY 83
9.2.1 LINAC 84
9.2.2 PROTON THERAPY 84
9.2.2.1 SYNCHROTRON 84
9.2.2.2 CYCLOTRON 84
9.2.3 CYBER KNIFE 84
9.2.4 GAMMA KNIFE 85
9.2.5 OTHERS 85
9.3 INTERNAL RADIOTHERAPY PRODUCTS 85
9.3.1 SEEDS 86
9.3.2 ELECTRONIC BRACHYTHERAPY 86
9.3.3 APPLICATORS 86
9.3.4 AFTERLOADERS 86
9.3.5 OTHERS 86
9.4 RADIOTHERAPY SOFTWARE 86
9.4.1 IMAGE GUIDING SOFTWARE 87
9.4.2 TREATMENT PLANNING SOFTWARE 87
9.4.3 PATIENT POSITIONING SOFTWARE 87
9.4.4 DOSAGE PLANNING SOFTWARE 88
9.4.5 OTHERS 88
9.5 SYSTEMIC RADIOTHERAPY 88
9.5.1 ALPHA EMITTERS 89
9.5.2 BETA EMITTERS 89
9.6 OTHERS 89
10 EUROPE RADIOTHERAPY MARKET, BY APPLICATION 90
10.1 OVERVIEW 91
10.2 BREAST CANCER 95
10.3 LUNG CANCER 96
10.4 PROSTATE CANCER 97
10.5 COLORECTAL CANCER 98
10.6 LYMPHOMA 99
10.7 LIVER CANCER 100
10.8 THYROID CANCER 101
10.9 BRAIN CANCER 101
10.10 CERVICAL CANCER 102
10.11 SPINE CANCER 103
10.12 OTHERS 104
11 EUROPE RADIOTHERAPY MARKET, BY END USER 105
11.1 OVERVIEW 106
11.2 HOSPITALS 109
11.3 RADIATION THERAPY CENTERS 109
11.4 SPECIALTY CLINICS 110
11.5 OTHERS 111
12 EUROPE RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 112
12.1 OVERVIEW 113
12.2 DIRECT TENDER 116
12.3 RETAIL SALES 116
12.4 OTHERS 117
13 EUROPE RADIOTHERAPY MARKET, BY REGION 118
13.1 EUROPE 119
13.1.1 GERMANY 128
13.1.2 FRANCE 132
13.1.3 U.K. 136
13.1.4 ITALY 140
13.1.5 SPAIN 144
13.1.6 NETHERLANDS 148
13.1.7 RUSSIA 152
13.1.8 SWITZERLAND 156
13.1.9 TURKEY 160
13.1.10 AUSTRIA 164
13.1.11 NORWAY 168
13.1.12 HUNGARY 172
13.1.13 LITHUANIA 176
13.1.14 IRELAND 180
13.1.15 POLAND 184
13.1.16 REST OF EUROPE 188
14 EUROPE RADIOTHERAPY MARKET: COMPANY LANDSCAPE 189
14.1 COMPANY SHARE ANALYSIS: EUROPE 189
15 SWOT ANALYSIS 190
16 COMPANY PROFILE 191
16.1 SIEMENS HEALTHCARE GMBH 191
16.1.1 COMPANY SNAPSHOT 191
16.1.2 REVENUE ANALYSIS 191
16.1.3 COMPANY SHARE ANALYSIS 192
16.1.4 PRODUCT PORTFOLIO 192
16.1.5 RECENT DEVELOPMENT 193
16.2 ELEKTA AB (PUB) 194
16.2.1 COMPANY SNAPSHOT 194
16.2.2 RECENT FINANCIALS 194
16.2.3 COMPANY SHARE ANALYSIS 195
16.2.4 PRODUCT PORTFOLIO 195
16.2.5 RECENT DEVELOPMENT 196
16.3 ACCURAY INCORPORATED 197
16.3.1 COMPANY SNAPSHOT 197
16.3.2 RECENT FINANCIALS 197
16.3.3 COMPANY SHARE ANALYSIS 198
16.3.4 PRODUCT PORTFOLIO 198
16.3.5 RECENT DEVELOPMENT 198
16.4 GENERAL ELECTRIC COMPANY 199
16.4.1 COMPANY SNAPSHOT 199
16.4.2 REVENUE ANALYSIS 199
16.4.3 COMPANY SHARE ANALYSIS 200
16.4.4 PRODUCT PORTFOLIO 200
16.4.5 RECENT DEVELOPMENT 200
16.5 IBA WORLDWIDE 201
16.5.1 COMPANY SNAPSHOT 201
16.5.2 RECENT FINANCIALS 201
16.5.3 COMPANY SHARE ANALYSIS 202
16.5.4 PRODUCT PORTFOLIO 202
16.5.5 RECENT DEVELOPMENT 202
16.6 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG) 203
16.6.1 COMPANY SNAPSHOT 203
16.6.2 REVENUE ANALYSIS 203
16.6.3 PRODUCT PORTFOLIO 204
16.6.4 RECENT DEVELOPMENT 204
16.7 ADVANCED ONCOTHERAPY 205
16.7.1 COMPANY SNAPSHOT 205
16.7.2 PRODUCT PORTFOLIO 205
16.8 ARIANE MEDICAL SYSTEMS LTD 206
16.8.1 COMPANY SNAPSHOT 206
16.8.2 PRODUCT PORTFOLIO 206
16.8.3 RECENT DEVELOPMENT 206
16.9 BRAINLAB 207
16.9.1 COMPANY SNAPSHOT 207
16.9.2 PRODUCT PORTFOLIO 207
16.9.3 RECENT DEVELOPMENT 207
16.10 CANON MEDICAL SYSTEMS CORPORATION 208
16.10.1 COMPANY SNAPSHOT 208
16.10.2 PRODUCT PORTFOLIO 208
16.10.3 RECENT DEVELOPMENT 208
16.11 CIVCO RADIOTHERAPY 209
16.11.1 COMPANY SNAPSHOT 209
16.11.2 PRODUCT PORTFOLIO 209
16.11.3 RECENT DEVELOPMENT 210
16.12 ECKERT & ZIEGLER BEBIG 211
16.12.1 COMPANY SNAPSHOT 211
16.12.2 RECENT FINANCIALS 211
16.12.3 PRODUCT PORTFOLIO 212
16.12.4 RECENT DEVELOPMENT 212
16.13 HITACHI, LTD. 213
16.13.1 COMPANY SNAPSHOT 213
16.13.2 REVENUE ANALYSIS 213
16.13.3 PRODUCT PORTFOLIO 214
16.13.4 RECENT DEVELOPMENT 214
16.14 INTRAOP MEDICAL, INC. 215
16.14.1 COMPANY SNAPSHOT 215
16.14.2 PRODUCT PORTFOLIO 215
16.14.3 RECENT DEVELOPMENT 216
16.15 ISORAY INC. 217
16.15.1 COMPANY SNAPSHOT 217
16.15.2 REVENUE ANALYSIS 217
16.15.3 PRODUCT PORTFOLIO 218
16.15.4 RECENT DEVELOPMENT 218
16.16 KONINKLIJKE PHILIPS N.V. 219
16.16.1 COMPANY SNAPSHOT 219
16.16.2 REVENUE ANALYSIS 219
16.16.3 PRODUCT PORTFOLIO 220
16.16.4 RECENT DEVELOPMENT 220
16.17 MEVION MEDICAL SYSTEMS 221
16.17.1 COMPANY SNAPSHOT 221
16.17.2 PRODUCT PORTFOLIO 221
16.17.3 RECENT DEVELOPMENT 221
16.18 MIRADA MEDICAL LIMITED 222
16.18.1 COMPANY SNAPSHOT 222
16.18.2 PRODUCT PORTFOLIO 222
16.18.3 RECENT DEVELOPMENT 222
16.19 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 223
16.19.1 COMPANY SNAPSHOT 223
16.19.2 REVENUE ANALYSIS 223
16.19.3 PRODUCT PORTFOLIO 224
16.19.4 RECENT DEVELOPMENT 224
16.20 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 225
16.20.1 COMPANY SNAPSHOT 225
16.20.2 PRODUCT PORTFOLIO 225
16.20.3 RECENT DEVELOPMENT 225
16.21 P-CURE 226
16.21.1 COMPANY SNAPSHOT 226
16.21.2 PRODUCT PORTFOLIO 226
16.21.3 RECENT DEVELOPMENT 226
16.22 PROTOM INTERNATIONAL 227
16.22.1 COMPANY SNAPSHOT 227
16.22.2 PRODUCT PORTFOLIO 227
16.22.3 RECENT DEVELOPMENT 227
16.23 PROVISION HEALTHCARE 228
16.23.1 COMPANY SNAPSHOT 228
16.23.2 PRODUCT PORTFOLIO 228
16.23.3 RECENT DEVELOPMENT 228
16.24 RAYSEARCH LABORATORIES 229
16.24.1 COMPANY SNAPSHOT 229
16.24.2 REVENUE ANALYSIS 229
16.24.3 PRODUCT PORTFOLIO 230
16.24.4 RECENT DEVELOPMENT 230
16.25 SIT - S.I.T. SORDINA IORT TECHNOLOGIES S.P.A. 231
16.25.1 COMPANY SNAPSHOT 231
16.25.2 PRODUCT PORTFOLIO 231
16.26 SUMITOMO HEAVY INDUSTRIES, LTD. 232
16.26.1 COMPANY SNAPSHOT 232
16.26.2 REVENUE ANALYSIS 232
16.26.3 PRODUCT PORTFOLIO 233
16.26.4 RECENT DEVELOPMENT 233
16.27 VIEWRAY TECHNOLOGIES, INC. (VIEWRAY) 234
16.27.1 COMPANY SNAPSHOT 234
16.27.2 RECENT FINANCIALS 234
16.27.3 PRODUCT PORTFOLIO 235
16.27.4 RECENT DEVELOPMENT 235
16.28 XOFT, A SUBSIDIARY OF ICAD, INC. 236
16.28.1 COMPANY SNAPSHOT 236
16.28.2 REVENUE ANALYSIS 236
16.28.3 PRODUCT PORTFOLIO 237
16.28.4 RECENT DEVELOPMENT 237
16.29 ZEISS INTERNATIONAL 238
16.29.1 COMPANY SNAPSHOT 238
16.29.2 PRODUCT PORTFOLIO 238
16.29.3 RECENT DEVELOPMENT 238
17 QUESTIONNAIRE 239
18 RELATED REPORTS 242
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
